Clinical Trial Update: TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada [Phase 4]

View source ↗

Summary

Phase 4 TOTEM trial reports switching from other NRTIs to once-daily Truvada in HIV infection; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV Infections | Phase 4 | Status: COMPLETED | Results posted: 2009-12-23